Evidence map›Paper›PMID 21755462›Full record

ReviewJournal of neural transmission (Vienna, Austria : 1996)2012

Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics.

Manfred Gerlach, Walter Maetzler, Karl Broich, Harald Hampel, Lucas Rems, Torsten Reum, Peter Riederer, Albrecht Stöffler, Johannes Streffer, Daniela Berg

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neural transmission (Vienna, Austria : 1996), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.Movement disorders : official journal of the Movement Disorder Society · 2017
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Laboratory assessments in the course of Parkinson's disease: a clinician's perspective.Journal of neural transmission (Vienna, Austria : 1996) · 2016
    Review
  20. Neurophysiological biomarkers for Lewy body dementias.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Manfred GerlachDepartment for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Füchsleinstrasse 15, 97080 Würzburg, Germany. manfred.gerlach@uni-wuerzburg.de
Walter Maetzler
Karl Broich
Harald Hampel
Lucas Rems
Torsten Reum
Peter Riederer
Albrecht Stöffler
Johannes Streffer
Daniela Berg
Federal Institute for Drugs and Medical Devices · DEUniversity of Würzburg · DEBoehringer Ingelheim (Germany) · DEGerman Center for Neurodegenerative Diseases · DEGoethe University Frankfurt · DEJanssen (Germany) · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson's disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies.

Indexed as

Drug Evaluation, PreclinicalNerve DegenerationAnimalsBiomarkersDisease ProgressionHumansNeuroprotective AgentsParkinson DiseaseBiomarkersNeuroprotective Agents

Identifiers

PMID21755462
PMCPMC3250615
OpenAlexW2091077834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.